GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immutep Limited
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its share price is driven by news of clinical trials and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Cancer women
Immutep (IMMP) is a biotech company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of oncological and autoimmune diseases. We classify it as "Women's Cancer." The chart below shows the dynamics in the cutting-edge immuno-oncology sector where it operates.
Broad Market Index - GURU.Markets
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Immutep compares to it.
Change in the price of a company, segment, and market as a whole per day
IMMP - Daily change in the company's share price Immutep Limited
Shares of Immutep, an Australian biotech company, are highly volatile. Change_co measures market reaction to clinical trial data in the field of immuno-oncology. This metric is an important component of formulas on System.GURU.Markets that evaluate international biotech companies.
Daily change in the price of a set of shares in a market segment - Cancer women
Immutep Limited is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMMP's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immutep is an Australian biopharmaceutical company developing immunotherapies for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and performance of Immutep shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immutep Limited
For Immutep Limited, the year-over-year trend is a story of developing a new approach in immuno-oncology. Its 12-month market capitalization is entirely dependent on clinical trial data for its lead drug, which targets the LAG-3 protein. Successful results in combination with other drugs could make it a key component of cancer treatment.
Annual dynamics of market capitalization of the market segment - Cancer women
Immutep Limited is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immutep is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immutep Limited
The performance of Immutep, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its immuno-oncology drugs, the success of which determines its future valuation and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Cancer women
Immutep is an Australian biotech company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. The chart below reflects overall investor sentiment in the oncology sector, where each new mechanism of action generates intense interest.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immutep Limited is an Australian biotech company developing immunotherapy for cancer treatment. Its shares move solely on news about clinical trials. The company's performance is completely disconnected from market cycles and represents a binary bet on the success of its scientific developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immutep Limited
Shares of Immutep, an Australian biotech company focused on immuno-oncology, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials for their drug candidates. The chart below is a prime example of how short-term scientific data and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer women
How does Immutep's performance compare to the broader biotech sector? This chart compares the immuno-oncology company's weekly stock price movements with the overall trend. This helps us understand whether the stock price movement driven by clinical trial news is the result of a unique scientific event or a reflection of general sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immutep is an Australian biotech company developing immunotherapy for cancer treatment. This chart shows how out of sync its weekly performance is with the market. Its stock moves are driven by clinical trial news, not macroeconomic data or S&P 500 trends.
Market capitalization of the company, segment and market as a whole
IMMP - Market capitalization of the company Immutep Limited
Immutep Limited's price chart is a bet on its innovative approach to cancer immunotherapy, targeting the LAG-3 protein. This Australian biotech company's market cap depends on the success of its clinical programs in treating various types of cancer. Its performance reflects hopes for the development of a new class of anti-cancer drugs.
IMMP - Share of the company's market capitalization Immutep Limited within the market segment - Cancer women
Immutep Limited is an Australian biotechnology company whose market share is based on its pioneering development of immunotherapeutic agents targeting the LAG-3 protein. Its market capitalization reflects the potential of this new approach for treating cancer and autoimmune diseases.
Market capitalization of the market segment - Cancer women
Here's a chart of the total market capitalization of biotech companies focused on the immune checkpoint protein LAG-3. Immutep is a pioneer in this field. The graph shows how the market values this promising but highly competitive field in immuno-oncology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a new approach to cancer immunotherapy. Immutep Limited's market capitalization reflects investors' faith in its unique molecule that stimulates the immune response. The line shows how a scientific platform targeting various tumor types is generating value in the global biotechnology industry.
Book value capitalization of the company, segment and market as a whole
IMMP - Book value capitalization of the company Immutep Limited
Immutep Limited's book value represents its scientific capital. The chart below reflects the valuation of its patent portfolio for immunotherapeutic drugs based on the LAG-3 protein. The line's growth signals success in clinical trials, which are the primary tangible embodiment of this biotech company's value.
IMMP - Share of the company's book capitalization Immutep Limited within the market segment - Cancer women
Immutep's resources are not massive factories, but cutting-edge laboratories and production facilities for the creation of innovative immunotherapeutic drugs. The chart shows the company's share of this scientific infrastructure, which serves as the physical foundation for developing new approaches to treating cancer and autoimmune diseases.
Market segment balance sheet capitalization - Cancer women
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Immutep, as a biotech company developing immunotherapy, appears "light." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Immutep is a biotech company developing immunotherapy for cancer treatment. Its assets are not factories, but patents for its platform and clinical trial data. The company's balance sheet is the value of its scientific approach to "orchestrating" the immune system. Against the backdrop of the overall economy, Immutep creates its intangible "shield."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immutep Limited
Immutep's balance sheet is its cash and patents. Its market capitalization is a bet on the success of its cancer immunotherapy platform. The MvsBCap_Co chart shows the vast gap between its modest assets and its grand "dream" of a new cancer treatment.
Market to book capitalization ratio in a market segment - Cancer women
Immutep is a biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Its value lies in its scientific platform. The chart shows the market's speculative assessment of its potential, which is hopeful of the success of its drugs in clinical trials.
Market to book capitalization ratio for the market as a whole
Immutep is a biotech company developing immunotherapeutic drugs for cancer and autoimmune diseases based on the LAG-3 protein. Its value lies in its scientific platform and the potential of its drug candidates. This chart demonstrates why investors are willing to pay a high premium for breakthrough approaches in immuno-oncology.
Debts of the company, segment and market as a whole
IMMP - Company debts Immutep Limited
For Immutep, a biotech company developing cancer immunotherapy, debt is a way to fund research. This chart illustrates how the company raises capital to conduct clinical trials of its drug candidates. In this field, where revenue may take years to arrive, debt is a vital resource for continued operations.
Market segment debts - Cancer women
Immutep is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Currently in clinical trials, the company relies entirely on funding to continue its research. This chart illustrates Immutep's funding strategy for advancing its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immutep Limited
Immutep is an Australian biotech company developing immunotherapy for cancer treatment. This chart shows its reliance on debt to fund clinical trials. For a company without stable revenue, high debt is a huge risk, entirely dependent on the success of its research and future partnerships.
Market segment debt to market segment book capitalization - Cancer women
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Clinical trials require significant capital. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risk profile of the overall biotech sector.
Debt to book value of all companies in the market
#VALUE!
P/E of the company, segment and market as a whole
P/E - Immutep Limited
This chart shows the valuation of Immutep, an Australian biotech developing immunotherapy for cancer. There is no price-to-earnings ratio (P/E). The company's value is based on the success of its lead drug in numerous clinical trials. The chart's dynamics depend entirely on news about these trials.
P/E of the market segment - Cancer women
This chart illustrates the average P/E for biotech companies. For Immutep, an Australian company, it serves as a backdrop. It shows the overall level of optimism in the immuno-oncology sector. This provides context for Immutep's valuation, which is a bet on the success of its specific scientific platform.
P/E of the market as a whole
Immutep is a biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its lead drug is designed to activate the immune system to fight tumors. This risk appetite chart helps understand how investors evaluate innovative approaches in immuno-oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immutep Limited
Immutep is an Australian biotechnology company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases based on the LAG-3 protein. This graph reflects expectations for its scientific platform. This estimate is dependent on clinical trial results and potential partnerships with major pharmaceutical companies for commercialization.
%20P%2FE%20Immutep%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immutep-Limited&v=1772513499779 "Chart of the company's future (projected) P/E Immutep Limited")
Future (projected) P/E of the market segment - Cancer women
Immutep is a biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This chart reflects the company's long-term profitability expectations compared to other biotech companies. It shows how highly the market perceives the potential of their lead drug, eftilagimod alpha, in various clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772513499789 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
Immutep is an Australian biotech company developing immunotherapy for the treatment of cancer and autoimmune diseases. Its valuation is dependent on the results of clinical trials. This market expectations chart is important as an indicator of investor willingness to fund long-term and risky scientific projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513499805 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immutep Limited
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its lead candidate is aimed at activating the immune system. Financial results reflect the costs of global clinical trials. This chart shows the history of the search for a new approach in immuno-oncology.
Profit of companies in the market segment - Cancer women
Immutep Limited is a biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Currently in clinical trials, it embodies the risks and promises of R&D. This biotech timeline shows the cumulative path from scientific discovery to commercialization, where years of unprofitable research can lead to a blockbuster.
Overall market profit
Immutep is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Like other companies in clinical trials, its value is determined by scientific data and the potential of its drugs, rather than by the macroeconomic indicators that drive the dynamics on this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immutep Limited
Immutep is a biotech company developing immunotherapeutic drugs for cancer and autoimmune diseases based on the LAG-3 protein. This chart reflects analyst expectations, which are entirely dependent on clinical trial results. The success of its lead drug, eftilagimod alfa, is key to future profitability.
%20profit%20of%20the%20company%20Immutep%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immutep-Limited&v=1772513499846 "Graph of future (projected) profit of the company Immutep Limited")
Future (predicted) profit of companies in the market segment - Cancer women
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This chart shows revenue forecasts for the women's health and oncology sector. It reflects expectations for breakthroughs in immunotherapy. This background is important for assessing the potential of the company's lead drug, eftilagimod alpha.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772513499860 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
Immutep is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Its valuation depends on the results of clinical trials. The overall economic situation, shown here, influences its valuation through the availability of capital and the willingness of large pharmaceutical companies to partner with or acquire promising developments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513499905 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immutep Limited
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. The company has no commercial revenue yet. This chart reflects investor valuations of its lead drug candidate, which is being studied in combination with other drugs to enhance their effectiveness.
P/S market segment - Cancer women
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa, targets immune system activation. This chart shows the average valuation in the sector, helping to understand how the market views the potential of this innovative immuno-oncology platform.
P/S of the market as a whole
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its lead candidate targets a novel mechanism for activating the immune response. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immutep Limited
Immutep is a biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. With no commercial products, its valuation is based on future potential. This chart reflects investors' confidence in its scientific platform and the potential commercial success of its drugs.
%20P%2FS%20Immutep%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immutep-Limited&v=1772513499956 "The graph of the company's future (projected) P/S Immutep Limited")
Future (projected) P/S of the market segment - Cancer women
Immutep is a biotech company developing immunotherapy drugs for the treatment of cancer and autoimmune diseases. This chart compares market expectations for its future revenue with those of other companies working in the field of women's cancer treatment. The valuation reflects investor confidence in its lead drug candidate, which targets the LAG-3 protein.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772513499962 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
Immutep is an Australian biotech company developing immunotherapy for cancer treatment. Its value is based on the potential of its scientific developments. The overall market optimism reflected in this chart is critical, as it provides access to the capital needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513499983 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immutep Limited
Immutep is an Australian biotechnology company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Currently in the clinical stage, its revenue comes from licensing fees and partnerships with major pharmaceutical companies. The chart reflects funding supporting its research.
Sales of companies in the market segment - Cancer women
Immutep is a biotech company developing innovative immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. Its lead candidate is undergoing clinical trials across multiple indications. Revenue is generated through partnerships. This chart demonstrates the interest in new immunotherapy mechanisms, where LAG-3 is one of the most promising areas.
Overall market sales
Immutep is an Australian biotech company developing immunotherapy for cancer treatment. Its value is determined solely by progress in clinical trials. While there's no direct correlation to this schedule, the overall state of financial markets, influenced by the economy, determines the company's ability to raise funds to continue research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immutep Limited
Immutep is an Australian biotechnology company developing immunotherapeutics based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. This chart reflects analyst expectations for clinical trial results and the commercial potential of this new approach in immuno-oncology.
%20sales%20of%20the%20company%20Immutep%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immutep-Limited&v=1772513500053 "Schedule of future (projected) sales of the company Immutep Limited")
Future (projected) sales of companies in the market segment - Cancer women
Immutep is a biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This chart displays the outlook for the oncology sector. It allows one to assess the potential of the company's lead drug and how clinical trial results may impact its future within the context of overall immunotherapy trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772513500086 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
Immutep Limited is a biotechnology company developing immunotherapies for the treatment of cancer and autoimmune diseases. This chart, reflecting the investment climate in the life sciences sector, is important for Immutep. The company's ability to attract funding for expensive clinical trials directly depends on investors' appetite for risk and long-term projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513500118 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immutep Limited
Immutep is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its core asset is its LAG-3 protein-based technology. This chart reflects the current phase of investment in clinical trials, which are necessary to confirm the efficacy and commercialize its scientific approach.
Market segment marginality - Cancer women
Immutep Limited is a biotechnology company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. Currently in the clinical stage, they are actively investing in research. This chart reflects the scale of these investments, which guarantees high potential profitability in the future.
Market marginality as a whole
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. The overall profitability picture is irrelevant for them. Their value lies in the potential of their lead drug, which can enhance the body's response to cancer. Success depends entirely on the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Immutep Limited
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This graph shows the team of scientists and clinicians. The growth of the team is a direct indicator of progress in its clinical programs and partnerships with major pharmaceutical companies.
Share of the company's employees Immutep Limited within the market segment - Cancer women
Immutep is a biotech company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. This chart shows the percentage of leading immuno-oncology scientists the company attracts. This demonstrates its focus on the new target and the team working on developing innovative drugs.
Number of employees in the market segment - Cancer women
Immutep Limited is a biotechnology company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. The data in the graph reflects employment in the immuno-oncology sector. The growing number of scientists in this field indicates the search for new targets for stimulating the immune system to fight diseases, a field in which Immutep is a pioneer.
Number of employees in the market as a whole
Immutep Limited is an Australian biotechnology company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. Its key development targets the protein LAG-3. This graph shows overall employment, and innovative companies like Immutep represent a global scientific frontier, creating jobs for world-class researchers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immutep Limited (IMMP)
Immutep Limited is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. Its valuation is based entirely on its scientific potential. This chart illustrates a model with a very high market capitalization per employee, as investors evaluate the future revenues of its platform, which is being developed by a small team of highly skilled scientists.
%20of%20the%20company%20Immutep%20Limited%20(IMMP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immutep-Limited-IMMP&v=1772513500448 "Chart of market capitalization per employee (in thousands of dollars) of the company Immutep Limited (IMMP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
Immutep is a biotech company developing immunotherapeutic drugs based on the LAG-3 protein for the treatment of cancer and autoimmune diseases. This metric reflects investors' faith in the company's scientific platform. The chart shows the future value the market places on each scientist working on this promising area of oncology.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772513500473 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
Immutep is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This chart reflects the market valuation of its scientific platform. The high per-employee price reflects investors' confidence in the potential of their key molecule, eftilagimod alpha.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513500550 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immutep Limited (IMMP)
Immutep (IMMP) is an Australian biotech company developing immunotherapies for the treatment of cancer and autoimmune diseases. This is R&D. This chart shows the "cost of science"—the negative profit (expenses) per scientist working on their lead candidate, "efti."
%20Chart%20Immutep%20Limited%20(IMMP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immutep-Limited-IMMP&v=1772513500640 "Company Profit Per Employee (in thousands of dollars) Chart Immutep Limited (IMMP)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
Immutep Limited is an Australian biotech company developing immunotherapeutic drugs for cancer treatment. Their key candidate is an immune cell activator. This chart shows the benchmark for biotech staff efficiency. It is important for assessing how effectively Immutep's scientific team utilizes investor capital.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772513500692 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
Immutep Limited is an Australian biotechnology company developing immunotherapies for the treatment of cancer and autoimmune diseases. They are currently in clinical trials. This chart shows the investment (R&D costs) per scientist working on their lead drug candidates. This investment is in intellectual property.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513500745 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immutep Limited (IMMP)
Immutep is a biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases. This chart reflects its focus on R&D. The lack of significant revenue per employee is typical for clinical-stage companies whose primary goal is to prove the efficacy of their molecules in clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immutep-Limited-IMMP&v=1772513500762 "Sales chart per company employee Immutep Limited (IMMP)")
Sales per employee in the market segment - Cancer women
Immutep (IMMP) is an Australian biotech company developing immunotherapies (based on the LAG-3 protein) for the treatment of cancer and autoimmune diseases. This chart shows the revenue (from partnerships) generated by each employee (scientist). This is an indicator of the productivity of their R&D platform compared to other biotechs in immuno-oncology.
Sales per employee for the market as a whole
Immutep Limited is an Australian biotech company developing immunotherapy for cancer treatment. Their lead drug is in clinical trials. They are an R&D company with no stable revenue. This graph (close to zero) reflects their investment in research: their research team is working on developing IP, which, if successful, should generate significant revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Immutep Limited (IMMP)
Immutep Limited is an Australian biotech developing immunotherapy (based on the LAG-3 protein) for cancer treatment. This chart shows bearish bets. Shorting biotechs in the clinical stage is a bet that their drugs will be ineffective in trials or will be outperform existing treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immutep-Limited-IMMP&v=1772513500819 "Short Shares Chart for the Company Immutep Limited (IMMP)")
Shares shorted by market segment - Cancer women
Immutep (IMMP) is an Australian biotech company developing immunotherapy (based on the LAG-3 protein) for the treatment of cancer and autoimmune diseases. This chart is a barometer of sentiment across the biotech industry. If investors are shorting the sector, they don't believe risky R&D will succeed. For Immutep, which relies on equity, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Immutep Limited (IMMP) is an Australian biotech company developing immunotherapy for cancer treatment. It's an early-stage speculative research company. This market pessimism chart shows when investors are risk-averse. IMMP shares, dependent on future clinical success, sell off during periods of panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immutep Limited (IMMP)
Immutep is an Australian biotech company working in the field of immuno-oncology (LAG-3). It's a speculative R&D bet. This chart measures the level of hype. It shows when the euphoria from trial data (overbought) or doubts about the platform (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immutep-Limited-IMMP&v=1772513500969 "RSI 14 indicator chart for the company's stock Immutep Limited (IMMP)")
RSI 14 Market Segment - Cancer women
Immutep Limited is an Australian biotech company developing immunotherapeutic drugs (based on LAG-3) for the treatment of cancer and autoimmune diseases. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by speculative expectations.
RSI 14 for the overall market
Immutep, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like Immutep are forced to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMMP (Immutep Limited)
Immutep is an Australian biotech company developing immunotherapeutic drugs (based on LAG-3) for the treatment of cancer and autoimmune diseases. This chart shows the average target price. Analysts' forecasts are based on clinical data for their lead drug (eftilagimod alpha) and partnerships with pharma giants.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMMP-Immutep-Limited&v=1772513501080 "A chart showing analyst consensus forecasts for the expected stock price. IMMP (Immutep Limited)")
The difference between the consensus estimate and the actual stock price IMMP (Immutep Limited)
Immutep (IMMP) is an Australian biotech company developing immunotherapy (based on LAG-3) for the treatment of cancer (breast and lung) and autoimmune diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their lead drug, eftilagimod alpha.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMMP-Immutep-Limited&v=1772513501103 "A chart showing the difference between the consensus forecast and the actual stock price. IMMP (Immutep Limited)")
Analyst consensus forecast for stock prices by market segment - Cancer women
Immutep (IMMP) is an Australian biotech company developing cancer immunotherapy. Its lead drug, eftilagimod alpha, "activates" the immune system to fight tumors. This chart shows general expectations for the oncology sector, reflecting whether experts believe in this new mechanism of immune activation.
Analysts' consensus forecast for the overall market share price
Immutep Limited is an Australian biotech company developing immunotherapeutic drugs (based on the LAG-3 protein) for the treatment of cancer and autoimmune diseases. This chart shows the overall "risk appetite." For Immutep, as a clinical-stage company, overall market optimism (an upward trend in the chart) is critical for raising the capital needed to fund expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immutep Limited
Immutep (IMMP) is an Australian biotech company at the forefront of immuno-oncology. Their key asset (eftilagimod alfa, efti) is an immune system activator (LAG-3 agonist), which they are testing in combination for cancer treatment. This chart is a clear indicator of faith in their R&D. It reflects the market's assessment of their clinical data and their partnerships with big pharma.
AKIMA Market Segment Index - Cancer women
Immutep Limited is an Australian biotech company developing immunotherapeutic drugs for the treatment of cancer and autoimmune diseases, focusing on the LAG-3 protein. This chart shows the average index for the oncology sector. It helps investors assess how Immutep's performance compares to the industry average for companies exploring new treatment options.
The AKIM Index for the overall market
Immutep is a biotech company specializing in LAG-3-based cancer immunotherapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story with global partnerships fits in with the overall economic trends impacting oncology research.
